New drug batoclimab shows promise for Hard-to-Treat Graves' disease
NCT ID NCT05907668
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This study tested a drug called batoclimab in 35 adults with Graves' disease whose thyroid hormone levels were still high despite taking standard antithyroid drugs. The goal was to see if batoclimab could help bring those levels back to normal or below over 24 weeks. Batoclimab works by blocking a protein that affects the immune system's attack on the thyroid.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- batoclimab
- What this could lead to
- If successful, batoclimab could offer a new treatment option for people with Graves' disease whose thyroid levels remain high despite standard therapy.
- What could go wrong
- This is a small, early-phase proof-of-concept study with only 35 participants. It may not show clear benefit, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Site Number - 6505
Mainz, 55131, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can a steroid shot make thyroid surgery safer?
- Targeting the immune system: a new antibody may free Graves' patients from daily drugs
- AI reads eye scans to spot thyroid disease activity and severity
- New drug aims to tame overactive thyroid in Graves' disease
- New drug aims to tame overactive thyroid in Graves' disease